Evidence map›Paper›PMID 39243109›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

Membrane RRM2-positive cells represent a malignant population with cancer stem cell features in intrahepatic cholangiocarcinoma.

Yongzhi Zhao, Shuting Xue, Danduo Wei, Jianjuan Zhang, Nachuan Zhang, Liping Mao, Niya Liu, Lei Zhao, Jianing Yan, Yifan Wang and 4 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yongzhi ZhaoThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Shuting XueThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Danduo WeiThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Jianjuan ZhangThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Nachuan ZhangThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Liping MaoThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Niya LiuThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Lei ZhaoShandong Cancer Hospital and Institute, Shandong Cancer Hospital of Shandong First Medical University, Jinan, Shandong Province, China.
Jianing YanThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Yifan WangThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Xiujun CaiThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Saiyong ZhuThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China.
Stephanie RoesslerInstitute of Pathology, Heidelberg University, University Hospital Heidelberg, Heidelberg, Germany.
Junfang JiThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Department of General Surgery in Sir Run Run Shaw Hospital Affiliated to School of Medicine, Cancer Center, Center for Life Sciences in Shaoxing Institute, Zhejiang University, Hangzhou, Zhejiang Province, China. junfangji@zju.edu.cn.ORCID http://orcid.org/0000-0002-3071-6494

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntrahepatic cholangiocarcinoma (iCCA) is one of the most lethal malignancies and highly heterogeneous. We thus aimed to identify and characterize iCCA cell subpopulations with severe malignant features.

methodsTranscriptomic datasets from three independent iCCA cohorts (iCCA cohorts 1-3, n = 382) and formalin-fixed and paraffin-embedded tissues from iCCA cohort 4 (n = 31) were used. An unbiased global screening strategy was established, including the transcriptome analysis with the activated malignancy/stemness (MS) signature in iCCA cohorts 1-3 and the mass spectrometry analysis of the sorted stemness reporter-positive iCCA cells. A group of cellular assays and subcutaneous tumor xenograft assay were performed to investigate functional roles of the candidate. Immunohistochemistry was performed in iCCA cohort 4 to examine the expression and localization of the candidate. Molecular and biochemical assays were used to evaluate the membrane localization and functional protein domains of the candidate. Cell sorting was performed and the corresponding cellular molecular assays were utilized to examine cancer stem cell features of the sorted cells.

resultsThe unbiased global screening identified RRM2 as the top candidate, with a significantly higher level in iCCA patients with the MS signature activation and in iCCA cells positive for the stemness reporter. Consistently, silencing RRM2 significantly suppressed iCCA malignancy phenotypes both in vitro and in vivo. Moreover, immunohistochemistry in tumor tissues of iCCA patients revealed an unreported cell membrane localization of RRM2, in contrast to its usual cytoplasmic localization. RRM2 cell membrane localization was then confirmed in iCCA cells via immunofluorescence with or without cell membrane permeabilization, cell fractionation assay and cell surface biotinylation assay. Meanwhile, an unclassical signal peptide and a transmembrane domain of RRM2 were revealed experimentally. They were essential for RRM2 trafficking to cell membrane via the conventional endoplasmic reticulum (ER)-Golgi secretory pathway. Furthermore, the membrane RRM2-positive iCCA cells were successfully sorted. These cells possessed significant cancer stem cell malignant features including cell differentiation ability, self-renewal ability, tumor initiation ability, and stemness/malignancy gene signatures. Patients with membrane RRM2-positive iCCA cells had poor prognosis.

conclusionsRRM2 had an alternative cell membrane localization. The membrane RRM2-positive iCCA cells represented a malignant subpopulation with cancer stem cell features.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaNeoplastic Stem CellsRibonucleoside Diphosphate ReductaseAnimalsBiomarkers, TumorCell Line, TumorFemaleHumansMaleMiceBiomarkers, TumorRibonucleoside Diphosphate Reductaseribonucleotide reductase M2Cell membrane localizationIntrahepatic cholangiocarcinomaRRM2Tumor heterogeneity

Identifiers

PMID39243109
PMCPMC11378576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.